# A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

Source: https://onco.cc/trials/nct06277219/  
OnCo record `nct06277219` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LAT010 in advanced solid tumours, run by Latticon Antibody Therapeutics, Inc, now recruiting.

## Summary

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) is a phase 1/2 interventional study registered as NCT06277219 by Latticon Antibody Therapeutics, Inc, with 150 participants planned, started 2024-06-05 and due to reach its primary completion in 2026-12. Interventions recorded: LAT010 and LAT010 + ICI.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06277219
- Phase: 1/2
- Setting: A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
- Sponsor: Latticon Antibody Therapeutics, Inc
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT06277219: https://clinicaltrials.gov/study/NCT06277219

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06277219.json